drugset / Trial / NCT01341717

Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin

NCT01341717

Phase 4 Completed 440 enrolled Jothydev's Diabetes and Research Centre
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the efficacy and safety of sitaglipin in the treatment of Type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control using metformin and insulin.

Timeline

Start
2012-02
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Glimepiride Small molecule 1 mg
Subject Glimepiride Small molecule 2 mg
Subject Glimepiride Small molecule 3 mg
Subject Sitagliptin Small molecule 100 mg
Background Insulin Protein / enzyme biologic 10 iu
Background Metformin Small molecule 1000 mg